Printer Friendly

EUROPEAN PATENTS GRANTED FOR AIDS VACCINE HGP-30

 BETHESDA, Md., Feb. 3 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) and Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), today announced that their jointly owned subsidiary, Viral Technologies, Inc. (VTI), has been granted a European patent covering VTI's HGP-30 AIDS vaccine. The title of the patent is "HTLV-III virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against AIDS virus and diagnostic test for the serological detection of the AIDS virus."
 The allowed claims will cover peptides from the p17 core protein of HIV, including HGP-30, the 30-amino acid peptide which is the key ingredient of the HGP-30 AIDS vaccine. Also covered are claims directed to immunogenic antigens in which the foregoing peptides are covalently bonded to an immunogenic carrier material, vaccines based on these peptides, antibodies specific to these peptides and monoclonal antibodies based thereon, antisera, and diagnostic kits and in vitro diagnostic assays.
 HGP-30 differs from other vaccine candidates in that it is a synthetic copy of a part of the p17 core protein of the HIV virus. It was chosen as a vaccine candidate because its sequence is highly conserved in many HIV strains and because it contains both T- and B- cell epitopes and therefore has the potential, as shown in VTI's ongoing human trials, to elicit both cell-mediated immunity as well as serum antibodies against the HIV virus.
 HGP-30 has been evaluated for safety in two clinical trials conducted with normal, HIV-negative individuals. The first trial was conducted at Kobler AIDS Center, London, and the second was conducted at the LAC-USC Medical Center and San Francisco General Hospital under the terms of California State Food and Drug regulations. The results of both studies showed HGP-30 to be well-tolerated.
 -0- 2/3/93
 /CONTACT: Geert Kersten of CEL-SCI Corporation, 703-549-5293, or Vincent F. Simmon, Ph.D., of Alpha 1 Biomedicals, Inc., 301-564-4400/


CO: CEL-SCI Corporation; Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

TW -- DC001 -- 2222 02/03/93 08:28 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1993
Words:327
Previous Article:ROCHESTER TEL INTRODUCES COMPETITION FOR LOCAL TELEPHONE SERVICE; COMPANY PLANS TO REORGANIZE
Next Article:OWENS & MINOR, INC. ANNOUNCES RECORD 1992 FOURTH QUARTER AND TWELVE-MONTH EARNINGS FROM CONTINUING OPERATIONS
Topics:


Related Articles
SAFETY TESTING OF AIDS VACCINE COMPLETED
NEW HUMAN STUDIES BEGIN WITH AIDS VACCINE CANDIDATE HGP-30
CEL-SCI CORPORATION ANNOUNCES CLEARANCE FOR AIDS TRIAL
CEL-SCI'S HGP-30 AIDS VACCINE SHOWS SIGNIFICANT PROTECTION AGAINST HIV CHALLENGE
KEY PRODUCT PATENT FOR CEL-SCI ALLOWED BY JAPANESE PATENT OFFICE
CEL-SCI ANNOUNCES PRESENTATION OF CLINICAL DETAILS OF AIDS STUDY WITH HGP-30 VACCINE AT XI INTERNATIONAL CONFERENCE ON AIDS
CEL-SCI CORPORATION PURCHASES ALL REMAINING RIGHTS TO HGP-30 AIDS VACCINE FROM FORMER JAPANESE PARTNER
Japanese Patent Office Issues Patent To CEL-SCI Corporation on Aids Diagnostic Kit
European Patent Issued to Bavarian Nordic A/S on MVA-BN(R).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters